188 related articles for article (PubMed ID: 28253340)
21. Race and mortality risk after radiation therapy in men treated with or without androgen-suppression therapy for favorable-risk prostate cancer.
Kovtun KA; Chen MH; Braccioforte MH; Moran BJ; D'Amico AV
Cancer; 2016 Dec; 122(23):3608-3614. PubMed ID: 27490845
[TBL] [Abstract][Full Text] [Related]
22. Hormone therapy for prostate cancer increases the risk of Alzheimer's disease: a nationwide 4-year longitudinal cohort study.
Jhan JH; Yang YH; Chang YH; Guu SJ; Tsai CC
Aging Male; 2017 Mar; 20(1):33-38. PubMed ID: 28067607
[TBL] [Abstract][Full Text] [Related]
23. Association between duration and type of androgen deprivation therapy and risk of diabetes in men with prostate cancer.
Crawley D; Garmo H; Rudman S; Stattin P; Häggström C; Zethelius B; Holmberg L; Adolfsson J; Van Hemelrijck M
Int J Cancer; 2016 Dec; 139(12):2698-2704. PubMed ID: 27557616
[TBL] [Abstract][Full Text] [Related]
24. Androgen deprivation therapy and the risk of parkinsonism in men with prostate cancer.
Young JWS; Sutradhar R; Rangrej J; Marras C; Fleshner N; Alibhai SMH
World J Urol; 2017 Sep; 35(9):1417-1423. PubMed ID: 28204918
[TBL] [Abstract][Full Text] [Related]
25. Risk of Alzheimer's Disease Among Senior Medicare Beneficiaries Treated With Androgen Deprivation Therapy for Prostate Cancer.
Baik SH; Kury FSP; McDonald CJ
J Clin Oncol; 2017 Oct; 35(30):3401-3409. PubMed ID: 28841388
[TBL] [Abstract][Full Text] [Related]
26. Risk of developing hypertension after hormone therapy for prostate cancer: a nationwide propensity score-matched longitudinal cohort study.
Wu YH; Jhan JH; Ke HL; Tseng SI; Chang YH; Yeh HC; Li CC; Lee YC
Int J Clin Pharm; 2020 Dec; 42(6):1433-1439. PubMed ID: 32951178
[TBL] [Abstract][Full Text] [Related]
27. Androgen Deprivation Therapy Use Increases the Risk of Heart Failure in Patients With Prostate Cancer: A Population-Based Cohort Study.
Kao HH; Kao LT; Li IH; Pan KT; Shih JH; Chou YC; Wu ST
J Clin Pharmacol; 2019 Mar; 59(3):335-343. PubMed ID: 30402905
[TBL] [Abstract][Full Text] [Related]
28. Association of androgen deprivation therapy and depression in the treatment of prostate cancer: A systematic review and meta-analysis.
Nead KT; Sinha S; Yang DD; Nguyen PL
Urol Oncol; 2017 Nov; 35(11):664.e1-664.e9. PubMed ID: 28803700
[TBL] [Abstract][Full Text] [Related]
29. Statin Use at the Time of Initiation of Androgen Deprivation Therapy and Time to Progression in Patients With Hormone-Sensitive Prostate Cancer.
Harshman LC; Wang X; Nakabayashi M; Xie W; Valenca L; Werner L; Yu Y; Kantoff AM; Sweeney CJ; Mucci LA; Pomerantz M; Lee GS; Kantoff PW
JAMA Oncol; 2015 Jul; 1(4):495-504. PubMed ID: 26181260
[TBL] [Abstract][Full Text] [Related]
30. The need for androgen deprivation therapy in patients with intermediate-risk prostate cancer treated with dose-escalated external beam radiation therapy.
Dong Y; Ruth KJ; Churilla TM; Viterbo R; Sobczak ML; Smaldone MC; Chen DY; Uzzo RG; Hallman MH; Horwitz EM
Can J Urol; 2017 Feb; 24(1):8656-8662. PubMed ID: 28263132
[TBL] [Abstract][Full Text] [Related]
31. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality.
Tsai HK; D'Amico AV; Sadetsky N; Chen MH; Carroll PR
J Natl Cancer Inst; 2007 Oct; 99(20):1516-24. PubMed ID: 17925537
[TBL] [Abstract][Full Text] [Related]
32. The impact of androgen-deprivation therapy (ADT) on the risk of cardiovascular (CV) events in patients with non-metastatic prostate cancer: a population-based study.
Gandaglia G; Sun M; Popa I; Schiffmann J; Abdollah F; Trinh QD; Saad F; Graefen M; Briganti A; Montorsi F; Karakiewicz PI
BJU Int; 2014 Dec; 114(6b):E82-E89. PubMed ID: 24612110
[TBL] [Abstract][Full Text] [Related]
33. Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial.
Fizazi K; Faivre L; Lesaunier F; Delva R; Gravis G; Rolland F; Priou F; Ferrero JM; Houede N; Mourey L; Theodore C; Krakowski I; Berdah JF; Baciuchka M; Laguerre B; Fléchon A; Ravaud A; Cojean-Zelek I; Oudard S; Labourey JL; Chinet-Charrot P; Legouffe E; Lagrange JL; Linassier C; Deplanque G; Beuzeboc P; Davin JL; Martin AL; Habibian M; Laplanche A; Culine S
Lancet Oncol; 2015 Jul; 16(7):787-94. PubMed ID: 26028518
[TBL] [Abstract][Full Text] [Related]
34. Androgen deprivation therapy and the risk of tenosynovitis in prostate cancer patients.
Liu JM; Liu DW; Chuang HC; Wu CT; Lin CY; Hsu RJ
Int Urol Nephrol; 2019 Jul; 51(7):1113-1119. PubMed ID: 31111393
[TBL] [Abstract][Full Text] [Related]
35. Statin reduces the risk of dementia in diabetic patients receiving androgen deprivation therapy for prostate cancer.
Liu JM; Chen TH; Chuang HC; Wu CT; Hsu RJ
Prostate Cancer Prostatic Dis; 2019 May; 22(2):276-283. PubMed ID: 30337635
[TBL] [Abstract][Full Text] [Related]
36. Androgen deprivation therapy and cardiovascular risk: No meaningful difference between GnRH antagonist and agonists-a nationwide population-based cohort study based on 2010-2013 French Health Insurance data.
Scailteux LM; Vincendeau S; Balusson F; Leclercq C; Happe A; Le Nautout B; Polard E; Nowak E; Oger E
Eur J Cancer; 2017 May; 77():99-108. PubMed ID: 28390298
[TBL] [Abstract][Full Text] [Related]
37. Serum testosterone level predicts the effective time of androgen deprivation therapy in metastatic prostate cancer patients.
Wang Y; Dai B; Ye DW
Asian J Androl; 2017; 19(2):178-183. PubMed ID: 26975487
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of the effectiveness of adding androgen deprivation to modern dose-escalated radiotherapy for men with favorable intermediate-risk prostate cancer.
Falchook AD; Basak R; Mohiuddin JJ; Chen RC
Cancer; 2016 Aug; 122(15):2341-9. PubMed ID: 27191936
[TBL] [Abstract][Full Text] [Related]
39. Androgen deprivation therapy and fracture risk in Chinese patients with prostate carcinoma.
Lee CH; Huang G; Chan PH; Hai J; Yeung CY; Fong CH; Woo YC; Ho KL; Yiu MK; Leung F; Lau TW; Tse HF; Lam KS; Siu CW
PLoS One; 2017; 12(2):e0171495. PubMed ID: 28158241
[TBL] [Abstract][Full Text] [Related]
40. Large institutional variations in use of androgen deprivation therapy with definitive radiotherapy in a population-based cohort of men with intermediate- and high-risk prostate cancer.
Ong WL; Foroudi F; Evans S; Millar J
BJU Int; 2017 Nov; 120 Suppl 3():35-42. PubMed ID: 28749017
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]